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Other factors that contribute to the stressful workload
of the Brazilian ATC is the complexity of the sectors that
controller's work with, unexpected traffic conflicts, the
necessity to deviate from English phraseology to solve
problems, time pressure, limitations and reliability of the
equipment, and sometimes a shift schedule that does not
coincide with the relationship between peak traffic and the
worker's circadian rhythm.
According to Vismari, the time spent by an air traffic
controller to detect a conflict in his/her jurisdiction, to
effectuate an adequate solution and to communicate the
instruction to the aircraft crew is 4.95 seconds on average.(3)
Thus, the air traffic controller works as part of a team in
complex sociotechnical and high-risk systems where most of
the common place concepts known in many other
professional activities cannot be applied in the same way.
Working intensively in a cognitive activity, air traffic
controllers should ensure that their conditions best fit this
very well known Latin quotation: "Mens sana in corpore
sano", which means "a healthy mind in a healthy body".
After all, the air traffic controller is the last link, ready to
consistently activate the system, looking for the best timely
solution when technology fails. Creativity is the air traffic
controller's differential when compared with technology.
This scientific comment gave us the opportunity to
present several nuances of an activity little described in
medicine. The article by Ribas et al.(4) demonstrates an aspect
peculiar to air traffic controllers.
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The diversity of clinical, hematological and genetic features among patients with
acute myeloid leukemia (AML) has been recognized for many decades. However, during
recent years, considerable progress has been made in defining new diagnostic and
prognostic markers. Among them, the detection of specific molecules in the leukemic cells
has special relevance and is mandatory for the identification of certain subtypes of myeloid
neoplasms.(1,2) In this context, flow cytometry-based immunophenotyping has had an
immense impact on the diagnosis and management of AML and has become a routine
procedure.
In the present issue of this journal, Alegretti et al. reported the analysis of the
association between expression of CD56 on myeloblasts and treatment outcome in a cohort
of 48 patients with AML treated in a single center in Brazil.(3) CD56 is the neural-cell adhesion
molecule (NCAM), which is a well known marker for natural killer (NK) cells, but is also
expressed on a subset of normal T cells. Alegretti et al. demonstrated that the expression of
CD56 was associated with worse prognosis. The overall survival (OS) of patients who
expressed CD56 (CD56+) was significantly shorter compared to patients who did not express
the marker (mean 4.0 versus 14.5 months; p-value = 0.03). In addition, CD56+ patients
presented a higher death rate during induction, even though the difference was not
significant (62.5% versus 27.5%; p-value = 0.097). The results may have been affected by
the small number of patients in the CD56+ group (n = 6) but the magnitude of the difference
in OS is too striking to be ignored. Their results corroborate the studies by Chang et al.(4)
and Baer et al.,(5) but in the latter the association between prognosis and CD56 expression
was restricted to patients with t(8;21)/RUNX1-RUNX1T1 whereas in the former the
association was between CD56 expression and abnormalities involving 11q23 and
extramedullary disease. To further complicate the issue, a recent manuscript by Montesinos
et al.(6) reported the prognostic relevance of CD56 in acute promyelocytic leukemia (APL).
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They analyzed 651 patients with APL of whom 72 expressed
CD56 (11%). CD56+ APL was significantly associated with
high white blood cell counts, low albumin levels, the BCR3
isoform and coexpression of the CD2, CD34, CD7, HLA-
DR, CD15 and CD117 antigens. For CD56+ APL, the 5-year
relapse rate was 22% compared with a 10% relapse rate for
CD56- APL (p-value = 0.006). CD56+ APL also showed a
greater risk of extramedullary relapse (p-value < 0.001).
The relationship between the expression of CD56 and
treatment outcome has also been analyzed in acute
lymphoblastic leukemia (ALL). Ravandi et al.(7) demonstrated
a high incidence of infiltration of the central nervous system
in adult patients with ALL. Dalmazzo et al.,(8) analyzing T-
cell ALL, reported that patients expressing CD56 were older,
expressed cytotoxic molecules at a higher frequency and
presented shorter OS compared to CD56- patients.
Taken together the existing published data suggest
that the expression of CD56 is associated with worse
prognosis in acute leukemias and the manuscript by
Alegretti et al., corroborates reports from different countries.
Nevertheless, the mechanisms underlying this association
are unclear. Moreover, it is not clear whether CD56+ AML
patients should receive a more intense treatment than those
that do not express CD56. At present, this matter should be
considered with caution, but, definitely there is opportunity
for future multicentric clinical trials to address this issue.
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HbS polymerization is a primary pathophysiological event in sickle cell anemia (SCA).
Hydroxyurea (HU) is one important therapy that offers broad benefits to a select group of
patients with severe symptoms. HU induces higher levels of HbF thereby inhibiting the
polymerization of HbS, acts on red blood cell hydration, vascular wall adherence and
suppresses granulocyte and reticulocyte counts.
It has been suggested that oxidative stress plays a key role in many
pathophysiological disorders and thus has gained increasing attention. Imbalance between
production and elimination of reactive oxygen species (ROS) can damage cell structures,
including lipids, membranes, proteins and nucleic acids resulting in cell death or altered cell
function. However, the role of free radicals is not fully known and most evidence is indirect;
consensual reference ranges and interpretation are lacking.
Although results are sometimes contradictory, patients with SCA are shown to have
high oxidative stress. Sickle cells spontaneously generate approximately two times more
ROS compared to normal red blood cells; this is associated with endothelial dysfunction,
inflammation and multiple organ damage and is related to the severity of clinical features.(1,2)
In addition, multiple transfusions cause accumulation of pathological non-transferrin-bound
iron that catalyzes the generation of ROS.
Monitoring oxidative stress involves different parameters associated to pro-oxidant
and antioxidant biomarkers. Methods differ according to analytical practicability,
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